Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

This study is testing a new drug called PMD-026 combined with a hormone-blocking drug (fulvestrant) in women with a type of metastatic breast cancer that is hormone receptor-positive (HR+), HER2-negative, and has a specific protein marker called RSK2. It targets cancers that have stopped responding to prior hormone therapies. **You may be eligible if...** - You have hormone receptor-positive, HER2-negative metastatic breast cancer - Your tumour tests positive for RSK2 - You have the normal ESR1 gene (not mutated) - Your cancer has progressed after a CDK4/6 inhibitor combined with endocrine therapy - You have received at least one prior hormone treatment for metastatic or locally advanced breast cancer - You have at least one measurable tumour - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have previously received chemotherapy for metastatic breast cancer - You have ESR1 gene mutations - Your cancer has spread to vital organs in a way that urgently requires chemotherapy - You have untreated or unstable brain metastases Talk to your doctor to see if this trial is right for you.